SMOFLIPID 20% (smoflipid) by Fresenius Kabi is acids. Approved for including term, preterm neonates, a source of calories and 4 more indications. First approved in 2016.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
SMOFLIPID 20% is an intravenous lipid emulsion containing a mixture of soybean oil, medium-chain triglycerides, olive oil, and fish oil, designed to provide essential fatty acids and calories for parenteral nutrition. It is indicated for term and preterm neonates when enteral nutrition is not possible, insufficient, or contraindicated. The drug works through beta oxidation of fatty acids to generate energy, while also supporting membrane structure, bioactive molecule production, and gene expression.
Product is at peak commercial maturity with moderate competitive pressure (30), positioning the brand team to focus on market retention and operational efficiency rather than growth initiatives.
acids. Fatty acids serve as an important substrate for energy production. The most common mechanism of action for energy production derived from fatty acid metabolism is beta oxidation. Fatty acids are also important for membrane structure and function, as precursors for bioactive molecules (such…
Lipid Emulsion
Worked on SMOFLIPID 20% at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients
Safety and Efficacy Study to Compare Smoflipid and Intralipid 20% in Pediatric Patients of 3 Months to 16 Years of Age
Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants
Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants?
Study Comparing the Safety and Tolerance of SMOFlipid 20% in Long-term Treatment With Parenteral Nutrition
Working on SMOFLIPID offers stability in a specialized, high-stakes therapeutic area (neonatal care), but limited job openings and peak-stage lifecycle mean fewer growth opportunities and smaller team expansion potential. Career value lies in deep expertise in parenteral nutrition, hospital systems relationships, and niche clinical marketing rather than broad portfolio exposure.